跳到正文
Silicon Republic· Laura Varley·· 2 天前AI 評分54

Isomorphic Labs 與 MSD 合作開展 AI 癌症藥物研究

Isomorphic Labs and MSD team up on AI-led cancer drug discovery

AI 導讀

Isomorphic Labs 與 MSD 合作開展癌症藥物研究,結合 AI 技術與 MSD 數據資源,尋找針對一項重要腫瘤靶點的小分子候選藥物。Isomorphic Labs 會把 MSD 的數據集用於其藥物設計引擎 IsoDDE,並透過計算模擬實驗產出藥物分子設計;MSD 將參與臨牀前及臨牀開發、製造,以及把因此產生的藥物推向市場。

正文

The partnership will see both organisations collaborate on oncology drug therapies designed to target small molecules.

Alphabet’s Isomorphic Labs and MSD are set to collaborate on a research project that will combine Isomorphic Labs’ AI technology with MSD’s data resources. 

The partnership will aim to “discover therapeutic small molecule candidates against an oncology target of strategic importance”. That is to say, Isomorphic Lab’ and MSD will work together to find potential new cancer drugs aimed at a prioritised target.

As part of the collaboration Isomorphic Labs will use in silico prediction, which is the use of computational or computer-simulated experiments used in drug discovery, to deliver drug molecule designs. The company will apply MSD’s data sets to its own drug design engine (IsoDDE).

MSD involvement will include pre-clinical and clinical development, manufacturing and bringing any resulting medicines to market.

Among the terms of the partnership agreement, Isomorphic Labs will receive an upfront payment from MSD and will also be eligible for payments based on the achievement of specified research, development, regulatory and commercial milestones. 

Earlier in the week Isomorphic Labs announced that the company had raised $5bn in Series C funding. 

The round was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz, several other new investors and a significant investment from Alphabet. The round also included participation from existing investors Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

Commenting on the partnership, Sarah Skerratt, the chief research officer at Isomorphic Labs, said, “Through this collaboration with MSD, we will apply our world-leading drug design engine to unlock significant discovery progress.

“By leveraging the generative and predictive power of the IsoDDE to address this challenging program, this collaboration highlights our companies’ shared commitment to innovation for the benefit of patient populations with unmet needs.”

George Addona, the senior vice-president and head of discovery, preclinical development and translational medicine at MSD Research Laboratories, said, “The key to successfully leveraging AI and ML for molecular invention lies in close coordination of wet-lab and dry-lab functions.

“By combining MSD’s substantial internal data capabilities and discovery expertise with Isomorphic Labs’ powerful modelling and compute capabilities, we aim to identify new ways to design and create better candidates faster.”

Don’t miss out on the knowledge you need to succeed. Sign up for the Daily Brief, Silicon Republic’s digest of need-to-know sci-tech news.

來源:Silicon Republic · siliconrepublic.com